Huabo Kaisheng Dapoxetine Hydrochloride Tablets Obtained First Domestic Approval

　　Pharmaceutical Network April 21, April 17, the new three-plate pharmaceutical company Guangdong Tynekang Pharmaceuticals issued a notice that the subsidiary Shandong Huapu Kaisheng recently received the State Drug Administration approved the issuance of hydrochloric acid daPositin tablets "drug registration approval." Hydrochloric acid dapositin is currently the only approved for the treatment of premature ejaculation (PE) of the chemical drugs, this approved product is the first in the country in accordance with the 4 types of imitation declaration, as if through the consistency evaluation, and for the domestic first imitation Table 1:
Basic strains Source: Company Announcement It is known that hydrochloric acid dapositine is a short-acting selective 5-serotonin reuptake inhibitor (SSRI), mainly applicable to the treatment of male premature ejaculation patients aged 18-64 years old Premature ejaculation (PE) is a common male sexual dysfunction disorder, the incidence of high, the patient's physical and mental and quality of life has a serious impact Hydrochloric acid dapositinis is currently the only approved for the treatment of premature ejaculation of chemical drugs, but also domestic and foreign "premature ejaculation diagnosis and treatment guide" the first line of treatment drugs, its clinical benefits, and low safety risk, with rapid effect, rapid removal and low drug accumulation and other advantages Figure 1: Sales of hydrochloric acid dapositine at the terminal of key urban public hospitals (unit: million yuan) source: Minet key city public hospital terminal competition pattern
announcement mentioned in the announcement, hydrochloric acid daPositin tablets are now officially listed in many countries and regions, approved for listing in China in 2010 This hydrochloric acid dapositin tablets is the first in china in accordance with the chemical drug 4 categories of declaration, and in accordance with the original research quality consistency evaluation requirements approved by the same varieties, for the domestic first imitation Up to now, the company has invested about 7.597 million yuan in research and development projects in the hydrochloric acid Dapositin tablet sliver at present, in the trial of hydrochloric acid dapositin tablets 4 types of imitation acceptance number also involved in Colum Pharmaceuticals, Xinlitai, Yangzijiang and other 4 pharmaceutical enterprises, according to cDE contractor time, the earliest declaration is Colum Pharmaceuticals, this time by Yantai Lu Yin Pharmaceuticals and Shandong Huaplatinum Kaisheng joint venture beyond source: Minet database, listed companies announced on April 17, the new three-plate pharmaceutical company Guangdong Tynekang issued a notice that the subsidiary Shandong Huapu Kaisheng recently received the State Drug Administration approved the issuance of hydrochloric acid daPositin tablets "
batch." Hydrochloric acid dapositin is currently the only approved for the treatment of premature ejaculation (PE) of the chemical drugs, this approved product is the first in the country in accordance with the 4 types of imitation declaration, as if through the consistency evaluation, and for the domestic first imitation it is known that hydrochloric acid dapositine is a short-acting selective 5-serotonin reuptake inhibitor (SSRI), mainly suitable for the treatment of 18-64 yearold male premature ejaculation patients Premature ejaculation (PE) is a common male sexual dysfunction disorder, the incidence of high, the physical and mental health and quality of life of patients have a serious impact Hydrochloric acid dapositinis is currently the only approved for the treatment of premature ejaculation of chemical drugs, but also domestic and foreign "premature ejaculation diagnosis and treatment guide" the first line of treatment drugs, its clinical benefits, and low safety risk, with rapid effect, rapid removal and low drug accumulation and other advantages Figure 1: The sales of the key city public terminal hydrochloric acid da positine (unit: million yuan) announcement, hydrochloric acid dapositin tablets are now officially listed in many countries and regions, in 2010 approved for listing in China This hydrochloric acid dapositin tablets is the first in china in accordance with the chemical drug 4 categories of declaration, and in accordance with the original research quality consistency evaluation requirements approved by the same varieties, for the domestic first imitation Up to now, the company has invested about 7.597 million yuan in research and development projects in the hydrochloric acid Dapositin tablet sliver at present, in the trial of hydrochloric acid dapositin tablets 4 types of imitation acceptance number also involved in Colum Pharmaceuticals, Xinlitai, Yangzijiang and other 4 pharmaceutical enterprises, according to cDE contractor time, the earliest declaration is Colum Pharmaceuticals, this time by Yantai Lu Yin Pharmaceuticals and Shandong Huaplatinum Kaisheng joint venture beyond Source: Internet Database, Public Company Announcement